Douglas T. Sheehy
Direktor/Vorstandsmitglied bei Aimmune Therapeutics UK Ltd.
Profil
Douglas T.
Sheehy is currently a Director at Aimmune Therapeutics UK Ltd.
He was previously an Executive Director-Legal & Corporate Law at CV Therapeutics, Inc. from 2002 to 2007, an Attorney at Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP from 1995 to 2000, and an Attorney at Brobeck, Phleger & Harrison LLP from 1994 to 1995.
From 2007 to 2016, he served as Secretary, Chief Administrative Officer & EVP at Codexis, Inc. and from 2016 to 2020, he was Secretary & General Counsel at Aimmune Therapeutics,.
Inc. Sheehy received his undergraduate degree from Dartmouth College in 1989 and his graduate degree from American University in 1994.
Aktive Positionen von Douglas T. Sheehy
| Unternehmen | Position | Beginn |
|---|---|---|
Aimmune Therapeutics UK Ltd.
 Aimmune Therapeutics UK Ltd. Pharmaceuticals: MajorHealth Technology Part of Stallergenes Greer Ltd., Aimmune Therapeutics UK Ltd. is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Cheltenham, UK. Aimmune Therapeutics was founded in 2015. | Direktor/Vorstandsmitglied | 31.03.2017 |
Ehemalige bekannte Positionen von Douglas T. Sheehy
| Unternehmen | Position | Ende |
|---|---|---|
| AIMMUNE THERAPEUTICS, INC. | General Counsel | 01.12.2020 |
| CODEXIS, INC. | Verwaltungsdirektor | 01.04.2016 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | General Counsel | 01.04.2007 |
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP
 Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP Miscellaneous Commercial ServicesCommercial Services Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP provides legal services. The firm is a business law firm that provides legal services to consumer, retail, information technology, communications, medical and life sciences industries. The company was founded in 1995 and is headquartered in Redwood City, CA. | Corporate Officer/Principal | 01.08.2000 |
| Brobeck, Phleger & Harrison LLP | Corporate Officer/Principal | 01.09.1995 |
Ausbildung von Douglas T. Sheehy
| Dartmouth College | Undergraduate Degree |
| American University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CODEXIS, INC. | Process Industries |
| Private Unternehmen | 5 |
|---|---|
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP Miscellaneous Commercial ServicesCommercial Services Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP provides legal services. The firm is a business law firm that provides legal services to consumer, retail, information technology, communications, medical and life sciences industries. The company was founded in 1995 and is headquartered in Redwood City, CA. | Commercial Services |
| Brobeck, Phleger & Harrison LLP | Commercial Services |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
Aimmune Therapeutics UK Ltd.
Aimmune Therapeutics UK Ltd. Pharmaceuticals: MajorHealth Technology Part of Stallergenes Greer Ltd., Aimmune Therapeutics UK Ltd. is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Cheltenham, UK. Aimmune Therapeutics was founded in 2015. | Health Technology |
